The Effect of Mankai on Glycemic Control Among Patients With T2D
Launched by BEN-GURION UNIVERSITY OF THE NEGEV · May 15, 2024
Trial Information
Current as of February 19, 2025
Active, not recruiting
Keywords
ClinConnect Summary
Type 2 diabetes (T2D), most commonly stemming from sustained obesity, adiposity, and a sedentary lifestyle, is strongly associated with increased cardiovascular risk. Glycated hemoglobin A1c (HbA1c), reflecting glycemic control, is tightly related to cardiovascular risk. In the recent decade, several antihyperglycemic medications have been shown to modify cardiovascular risk among patients with established cardiovascular disease. Maintaining a healthy diet, preferably a Mediterranean-like diet, rich in plant-based protein and low in meat products, is the first-line intervention to promote g...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 30 years
- • A formal diagnosis of T2D (126mg/dl fasting glucose or higher, or HbA1c\>6.5%) or taking T2D medications with HbA1c levels over 7%
- • Medication stability for at least 3 months prior to Intervention initiation
- • Adherence to medical follow-up in primary care clinic or diabetes-centered outpatient services
- Exclusion Criteria:
- • HbA1c lower than 7% or higher than 10%
- • Known insulinopenia
- • Treatment with coumadin (warfarin)
- • Advanced renal failure
- • Significantly disturbed liver enzymes (liver transaminases or bilirubin levels more than time three upper-normal-limit)
- • A significant illness that might require hospitalization
- • Regular Mankai consumption
- • State of pregnancy or lactation
- • Presence of active cancer or chemotherapy treatment in last three years
- • Participation in another trial
Trial Officials
Idit Liberty
Principal Investigator
Soroka University Medical Center
Iris Shai
Study Director
Ben-Gurion University of the Negev
About Ben Gurion University Of The Negev
Ben-Gurion University of the Negev (BGU) is a leading research institution located in Israel, dedicated to advancing knowledge and innovation in various fields, including health sciences, engineering, and environmental studies. With a strong emphasis on interdisciplinary collaboration, BGU fosters a dynamic research environment that integrates academic excellence with practical applications. The university is committed to addressing global challenges through cutting-edge clinical trials and studies, leveraging its expertise to improve healthcare outcomes and contribute to the advancement of medical science. BGU’s robust infrastructure and partnerships with industry and healthcare organizations position it as a pivotal player in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Be'er Sheva, , Israel
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0